Delcath is a medical company that makes the HEPZATO KIT and CHEMOSAT for treating cancers in the liver. It last closed at $18.79 on Nov 20, down 2.34% on the day. The next earnings report for DCTH is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, DCTH reported EPS of $0.17 on revenue of $35.1M, with revenue up 70.7% from a year ago. Over its last 8 reports the stock moved an average of 12.6% the session after earnings. Over the last 12 months DCTH insiders bought $189K of stock on the open market and sold $489K, according to SEC Form 4 filings.
AI Auto Pilots
Is DCTH in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold DCTH.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on DCTHStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
DCTH · as of the Nov 20 close · updated each morning
Uptrend
The stock is 8% above its 20 day and 14% above its 50 day average. It is 31% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 58). The nearest support is the Pivot S1 at $18.42, and the nearest resistance the Pivot at $18.88.
Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 5.6%/day
Key levels
$22.5152 week high+19.8%
$22.51Swing high (Nov 12)+19.8%
$19.25Pivot R1+2.4%
$18.88Pivot+0.5%
$18.79Last close
$18.42Pivot S1−2.0%
$17.3420 day average−7.7%
$16.51Swing low (Aug 17)−12.1%
$16.2250 day average−13.7%
$15.46100 day average−17.7%
$12.95200 day average−31.1%
$8.1252 week low−56.8%
Indicators
RSI (14)
57.76
Middle of its range
Neutral
MACD
1.22
Above its signal line
Bullish
Stochastic
61.3
Middle of its range
Neutral
ADX (14)
34.3
Trending up
Williams %R
-44.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
36.5
Oversold below −100, overbought above 100
Neutral
Rate of change
+25.9%
Change over 10 sessions
Bullish
ATR (14)
$1.06
Typical daily range, 5.7% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Uptrend, nearing overbought
Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityNormal, 8.9%/day
Key levels
$22.5152 week high+19.8%
$22.51Swing high (Nov 12)+19.8%
$19.25Pivot R1+2.4%
$18.88Pivot+0.5%
$18.79Last close
$18.42Pivot S1−2.0%
$17.3420 day average−7.7%
$16.51Swing low (Aug 17)−12.1%
$16.2250 day average−13.7%
$15.46100 day average−17.7%
$12.95200 day average−31.1%
$8.1252 week low−56.8%
Indicators
RSI (14)
65.73
Strong, overbought above 70
Neutral
MACD
1.37
Above its signal line
Bullish
Stochastic
61.6
Middle of its range
Neutral
ADX (14)
33.6
Trending up
Williams %R
-43.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
170.7
Oversold below −100, overbought above 100
Overbought
Rate of change
+18.1%
Change over 10 sessions
Bullish
ATR (14)
$1.68
Typical daily range, 8.9% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for DCTH
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how DCTH did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow DCTH usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for DCTHHow many large options trades hit DCTH, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in DCTH in the last 90 days.
From SEC Form 4 filings by DCTH's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DCTH is in one of them and how their past DCTH trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Delcath Systems
Delcath is a medical company focused on treating cancers that have spread to the liver or started there. Its lead product is the HEPZATO KIT, a combined drug and device treatment approved in the United States for adults with uveal melanoma that has spread to the liver. In Europe, Delcath sells CHEMOSAT, a device used at medical centers to deliver treatment to the liver. Its treatments are performed by interventional radiologists, and the company is based in Queensbury, New York.